Research Topics
Species | David FrankSummaryAffiliation: Harvard University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residuesD A Frank
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
J Clin Invest 100:3140-8. 1997..In summary, the constitutive serine phosphorylation of STAT1 and STAT3 is present in all CLL samples tested to date, although the physiologic significance of this modification remains to be determined...- STAT3 as a central mediator of neoplastic cellular transformationDavid A Frank
Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School and Brigham and Women s Hospital, Boston, MA 02115, USA
Cancer Lett 251:199-210. 2007..Since normal cells are relatively tolerant of interruption in STAT3 signaling, these findings suggest that STAT3 may also be an excellent target for the molecular therapy of cancer... - Targeting transcription factors for cancer therapyDavid A Frank
Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medical Oncology, Mayer 522B, 44 Binney Street, Boston, MA 02115, USA
IDrugs 12:29-33. 2009.... - The treatment and outcome of cancer patients with thromboses on central venous cathetersD A Frank
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
J Thromb Thrombolysis 10:271-5. 2000..A prospective trial to evaluate these approaches may be worthwhile so that the use of unnecessary procedures may be avoided in this patient population... - STAT signaling in the pathogenesis and treatment of cancerD A Frank
Department of Adult Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts 02115, USA
Mol Med 5:432-56. 1999..Thus, elucidation of cellular and biochemical processes in tumors has enhanced our understanding of the pathogenesis of malignancies and may provide the basis for significant advances in therapy... - Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signalingD A Frank
Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
Nat Med 5:444-7. 1999..Thus, STAT1 may be a useful target in the development of new immunosuppressive and antineoplastic agents... - Genome-wide analysis of STAT target genes: elucidating the mechanism of STAT-mediated oncogenesisJames V Alvarez
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer Biol Ther 3:1045-50. 2004..Analysis of these targets can provide insight into mechanisms of neoplastic transformation, and may shed light on new strategies for targeted therapy... - Reciprocal effects of STAT5 and STAT3 in breast cancerSarah R Walker
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Mol Cancer Res 7:966-76. 2009.... - Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapyDoris Germain
Division of Hematology Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, New York, USA
Clin Cancer Res 13:5665-9. 2007..Thus, elucidating the functions of STAT3 and developing agents to inhibit this protein remain important scientific and clinical challenges... - Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumorsJames V Alvarez
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer Res 65:5054-62. 2005..Finally, we showed that STAT3 is required for the expression of these genes in a breast cancer cell line. Taken together, these results identify a cohort of STAT3 targets that may mediate its role in oncogenesis... - STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1Traci E Battle
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney St, Boston, MA 02115, USA
Blood 102:3016-24. 2003..This study implicates STAT transcription factors as important mediators of Bryostatin 1-induced differentiation of CLL cells and could possibly lead to improved therapeutic approaches for the treatment of CLL... - Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cellsEllen Weisberg
Department of Medical Oncology Hematologic Neoplasia, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
PLoS ONE 6:e25351. 2011..Thus, there is a need for identification of molecular mechanisms of clinical resistance to these drugs. In response, we characterized MOLM13 AML cell lines made resistant to two structurally-independent FLT3 inhibitors... - StAT signaling in cancer: insights into pathogenesis and treatment strategiesDavid A Frank
Department of Adult Oncology, Dana-Farber Cancer Institute, Departments of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA
Cancer Treat Res 115:267-91. 2003 - Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identificationErik A Nelson
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
J Biol Chem 279:54724-30. 2004.... - Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutantsHeidi Greulich
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
PLoS Med 2:e313. 2005..The presence of mutations correlates with tumor sensitivity to the EGFR inhibitors erlotinib and gefitinib, but the transforming potential of specific mutations and their relationship to drug sensitivity have not been described... - A SnoN-Ccd1 pathway promotes axonal morphogenesis in the mammalian brainYoshiho Ikeuchi
Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA
J Neurosci 29:4312-21. 2009..These findings define a novel SnoN-Ccd1 link that promotes axonal growth in the mammalian brain, with important implications for axonal development and regeneration... - In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic responseTraci E Battle
Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
Clin Cancer Res 9:2166-72. 2003..CONCLUSION: This study indicates that STAT signaling may be an important mediator of biological treatments, such as CD154 gene therapy, and that early STAT1 activation may predict response to this novel treatment... - Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer modelYuki Ishii
Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA
J Natl Cancer Inst 98:1238-47. 2006..In addition, bortezomib can amplify the proapoptotic function of cyclin D1, raising the possibility that cyclin D1 levels may be a marker for predicting the response to this novel drug... - IL-6-induced survival of colorectal carcinoma cells is inhibited by butyrate through down-regulation of the IL-6 receptorHanna Yuan
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Carcinogenesis 25:2247-55. 2004..These experiments indicate that IL-6 may play an important role in the pathogenesis of colorectal cancers, and that butyrate may exert its protective effect by specifically blocking IL-6-induced signaling events... - Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasivenessNuria de la Iglesia
Department of Pathology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
J Neurosci 28:5870-8. 2008..These studies suggest that STAT3 activation or IL8 inhibition may have potential in patient-tailored treatment of PTEN-deficient brain tumors... - IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivoEmmanuel Zorn
Division of Hematologic Malignancies, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Blood 108:1571-9. 2006..Our findings support the clinical evaluation of low-dose IL-2 to selectively modulate CD4+CD25+ Tregs and increase expression of FOXP3 in vivo... - The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cellsTraci E Battle
Department of Medical Oncology, Mayer 522B, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Blood 106:690-7. 2005..These data indicate that honokiol is a potent inducer of apoptosis in B-CLL cells and should be examined for further clinical application either as a single agent or in combination with other anticancer agents... - Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptorJames V Alvarez
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
Cancer Res 66:3162-8. 2006..Thus, STAT3 is a critical mediator of the oncogenic effects of somatic EGFR mutations and targeting STAT3 may be an effective strategy for treating tumors characterized by these mutations... - Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivoJonathan W Friedberg
James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
Leuk Res 28:139-47. 2004..Larger studies are indicated to determine optimal timing of STAT1 assessment, and if changes in STAT1 represent an in vivo indicator of response to purine analog therapy... - Interleukin-13 induction of 15-lipoxygenase gene expression requires p38 mitogen-activated protein kinase-mediated serine 727 phosphorylation of Stat1 and Stat3Bo Xu
Department of Cell Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Mol Cell Biol 23:3918-28. 2003..Both of these events are important steps in IL-13-induced 15-LO expression in human monocytes... - Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cellsHajime Isomoto
Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Hepatology 42:1329-38. 2005..In conclusion, we have directly demonstrated a STAT3 regulatory element in the Mcl-1 promoter. Downregulation of Mcl-1 transcription by inhibiting this cascade is a potential strategy for the treatment of this cancer... - A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cellsNeil E Kay
Mayo Clinic, Stabile 628, 200 First Street SW, Rochester, MN 55905, USA
Leuk Res 29:1009-18. 2005..These studies suggest that the IL-4R, on B-CLL cells, can serve as a unique molecular target for directing cytotoxic agents in the therapy of B-CLL...
Research Grants
- STAT SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIADavid Frank; Fiscal Year: 2003..As a result of these experiments, we plan to discern the role of STATs in the abnormal growth of CLL cells, and to identify targets for novel and specific therapies. ..
- High Throughput Screening for Modulators of STAT5 (RMI)David Frank; Fiscal Year: 2004..The ultimate goal is the development of compounds that will act as targeted therapies for human cancers. ..
- STAT3 in the Pathogenesis and Treatment of Pancreatic CancerDavid Frank; Fiscal Year: 2007..We will test these drugs to determine whether they can be prototypes for a novel targeted form of therapy for this disease. ..